Routine board refresh with no operational or financial implications. No actionable trading signal; monitor upcoming quarterly filings for any strategic shifts.
VIR drugs
VIR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $8.52entry
- T+1 · 5mo ago +1.06%α +0.52% · $8.61
- T+5 · 5mo ago +9.15%α +8.72% · $9.30
- T+20 · 4mo ago +21.36%α +19.47% · $10.34
- T+60 · 2mo ago +31.22%α +27.40% · $11.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology appointed Timothy Coughlin, CPA, as a new Class III director and Audit Committee Chair, expanding the board from 7 to 8 members. This is a routine governance change with no financial impact or strategic implications disclosed.
Key Facts
- Board expanded from 7 to 8 members; Timothy Coughlin appointed to fill new vacancy
- Coughlin will serve as Class III director until 2028 annual meeting and as Audit Committee Chair
- No arrangement or understanding with any person triggered the appointment; no related party transactions
- Coughlin receives standard non-employee director compensation per existing policy, including stock option and RSU grants under the 2019 Equity Incentive Plan
Financial Impact
Standard director compensation; no material financial impact disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-042237 |
| Document: 0001628280-26-042237-index-headers.html | 0001628280-26-042237 |
| Document: 0001628280-26-042237-index.html | 0001628280-26-042237 |
| Document: 0001628280-26-042237.txt | 0001628280-26-042237 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers